On Tuesday, September 19, 2017, the Oncologic Drugs Advisory Committee (ODAC) split their vote, by a vote of 6-Yes to 6-No, with no abstentions, on the benefit-risk profile of Sutent (sunitinib malate), submitted by C.P. Pharmaceuticals International CV, represented by Pfizer, Inc. (authorized US agent) for the proposed indication of adjuvant treatment of adult patients at high risk of recurrent renal cell carcinoma (RCC) following nephrectomy.
Back to All Events
Earlier Event: September 14Anesthetic and Analgesic Drugs Advisory Committee and Drug Safety and Risk Management Advisory Committee
Later Event: September 28Peripheral and Central Nervous System Drugs Advisory Committee